Levokast AX Tablet is a combination medication containing Ambroxol (75mg), Levocetirizine (5mg), and Montelukast (10mg), formulated to provide comprehensive relief in respiratory conditions characterized by cough, allergy, and inflammation. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency and easing expectoration. Levocetirizine, a potent third-generation antihistamine, competitively inhibits peripheral H1 receptors, effectively reducing symptoms associated with allergic rhinitis and urticaria such as sneezing, nasal congestion, and itching, without causing significant sedation. Montelukast, a leukotriene receptor antagonist, blocks leukotriene D4 at the cysteinyl leukotriene receptor, mitigating bronchoconstriction, inflammation, and edema in the airways, thus improving lung function and reducing asthma exacerbations. The synergistic action of these three active ingredients makes Levokast AX suitable for managing chronic respiratory disorders including asthma, allergic rhinitis, and bronchitis with productive cough. It is recommended to be used under medical supervision, with dosage tailored to individual patient needs. Caution is advised in patients with hepatic impairment, and potential side effects include gastrointestinal discomfort, headache, and drowsiness.